Literature DB >> 17235586

Systemic immune dysfunction in pancreatic cancer patients.

Bertram Poch1, Errki Lotspeich, Marco Ramadani, Susanne Gansauge, Hans G Beger, Frank Gansauge.   

Abstract

BACKGROUND AND AIMS: We investigated the immune status in 32 pancreatic cancer patients (PC) in comparison with healthy controls (HC).
MATERIALS AND METHODS: Using flow cytometry, peripheral blood lymphocytes (PBL) were characterized by the expression of surface markers for T helper cells (CD4), T suppressor cells (CD8), B cells (CD19) and NK cells (CD56). The blastogenic response of PBL was analyzed after stimulation with concavalin A (ConA), phytohemagglutinin (PHA), pokeweed mitogen (PWM) and anti-CD3 antibodies. The serum levels of TNF-alpha, IL-1beta, IL-2, IL-10, IL-12, IL-18, IL-1RA, sIL-2R and TGF-beta were determined by ELISA.
RESULTS: No differences in the distribution of peripheral immunocytes in PC were found, whereas the blastogenic response of peripheral blood lymphocytes (PBL) after stimulation with PHA or anti-CD3 antibodies was significantly decreased in PC. In PC, we found reduced serum levels of IL-2 and significantly elevated levels of TNF-alpha, TGF-beta1, IL-10, IL-2R, IL-1beta and IL-1RA.
CONCLUSION: These data provide evidence for a systemic immune dysfunction in pancreatic cancer patients characterized by a shift towards a T helper cell type 2 cytokine profile, a significant elevation of substances related to T cell suppression and a reduced blastogenic response to PHA and anti-CD3 antibodies of PBL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17235586     DOI: 10.1007/s00423-006-0140-7

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  20 in total

1.  Where have all the T cells gone? Mechanisms of immune evasion by tumors.

Authors:  J Finke; S Ferrone; A Frey; A Mufson; A Ochoa
Journal:  Immunol Today       Date:  1999-04

Review 2.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

3.  Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma.

Authors:  F Gansauge; S Gansauge; B Rau; A Scheiblich; B Poch; M H Schoenberg; H G Beger
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

Review 4.  The host-tumor immune conflict: from immunosuppression to resistance and destruction.

Authors:  S Chouaib; C Asselin-Paturel; F Mami-Chouaib; A Caignard; J Y Blay
Journal:  Immunol Today       Date:  1997-10

5.  Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle.

Authors:  J J Smith; R Derynck; M Korc
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

6.  Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival.

Authors:  Graziella Bellone; Carlo Smirne; Francesco Angelo Mauri; Elena Tonel; Anna Carbone; Alessandra Buffolino; Luca Dughera; Antonio Robecchi; Mario Pirisi; Giorgio Emanuelli
Journal:  Cancer Immunol Immunother       Date:  2005-08-11       Impact factor: 6.968

7.  High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients.

Authors:  Friedrich H Schmitz-Winnenthal; Christine Volk; Kaspar Z'graggen; Luis Galindo; Daniel Nummer; Yvonne Ziouta; Marianna Bucur; Jürgen Weitz; Volker Schirrmacher; Markus W Büchler; Philipp Beckhove
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

8.  A prospective randomized study using adjuvant locoregional chemoimmunotherapy in combination with surgery for pancreatic carcinoma.

Authors:  N J Lygidakis; A E Berberabe; N Spentzouris; G Dedemadi; T Kalligas; G Loukas; V Sotiropoulou
Journal:  Hepatogastroenterology       Date:  1998 Nov-Dec

9.  Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients.

Authors:  C Asselin-Paturel; H Echchakir; G Carayol; F Gay; P Opolon; D Grunenwald; S Chouaib; F Mami-Chouaib
Journal:  Int J Cancer       Date:  1998-07-03       Impact factor: 7.396

10.  Interleukin 1beta-converting enzyme (caspase-1) is overexpressed in adenocarcinoma of the pancreas.

Authors:  S Gansauge; F Gansauge; Y Yang; J Müller; T Seufferlein; M Ramadani; H G Beger
Journal:  Cancer Res       Date:  1998-07-01       Impact factor: 12.701

View more
  13 in total

1.  The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis.

Authors:  Maryse Dagenais; Jeremy Dupaul-Chicoine; Todd Douglas; Claudia Champagne; Alexandre Morizot; Maya Saleh
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

Review 2.  Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer.

Authors:  P Goedegebuure; J B Mitchem; M R Porembka; M C B Tan; B A Belt; A Wang-Gillam; W E Gillanders; W G Hawkins; D C Linehan
Journal:  Curr Cancer Drug Targets       Date:  2011-07       Impact factor: 3.428

Review 3.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

Review 4.  Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials.

Authors:  Alessandro Paniccia; Justin Merkow; Barish H Edil; Yuwen Zhu
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

5.  Proteome variations in pancreatic stellate cells upon stimulation with proinflammatory factors.

Authors:  Aseel J Marzoq; Nathalia Giese; Jörg D Hoheisel; Mohamed Saiel Saeed Alhamdani
Journal:  J Biol Chem       Date:  2013-10-02       Impact factor: 5.157

6.  Protein Signatures and Tissue Diagnosis of Pancreatic Cancer.

Authors:  Patrick W Underwood; Michael H Gerber; Kathy Nguyen; Daniel Delitto; Song Han; Ryan M Thomas; Christopher E Forsmark; Jose G Trevino; William E Gooding; Steven J Hughes
Journal:  J Am Coll Surg       Date:  2019-10-28       Impact factor: 6.113

7.  Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls.

Authors:  Katrina S Pedersen; William R Bamlet; Ann L Oberg; Mariza de Andrade; Martha E Matsumoto; Hui Tang; Stephen N Thibodeau; Gloria M Petersen; Liang Wang
Journal:  PLoS One       Date:  2011-03-24       Impact factor: 3.240

8.  Prognostic significance of erythropoietin in pancreatic adenocarcinoma.

Authors:  Thilo Welsch; Stefanie Zschäbitz; Verena Becker; Thomas Giese; Frank Bergmann; Ulf Hinz; Shereen Keleg; Anette Heller; Bence Sipos; Ursula Klingmüller; Markus W Büchler; Jens Werner; Nathalia A Giese
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

9.  Effect of surgery on pancreatic tumor-dependent lymphocyte asset: modulation of natural killer cell frequency and cytotoxic function.

Authors:  Francesco Iannone; Alessandra Porzia; Giovanna Peruzzi; Patrizia Birarelli; Bernardina Milana; Luca Sacco; Giuseppe Dinatale; Nadia Peparini; Giampaolo Prezioso; Simone Battella; Roberto Caronna; Stefania Morrone; Gabriella Palmieri; Fabrizio Mainiero; Piero Chirletti
Journal:  Pancreas       Date:  2015-04       Impact factor: 3.327

Review 10.  Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.

Authors:  Yandiswa Yolanda Yako; Deirdré Kruger; Martin Smith; Martin Brand
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.